Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-28 15:06:37 - browse：652

Jakub Porzycki/NurPhoto via AP

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the fallout from Pfizer’s downbeat update, a new entrant in obesity research, and an orthogonal CRISPR business.

The need-to-know this morning

Apellis Pharmaceuticals said a European advisory committee is expected to recommend against the approval of Syfovre, its eye drug for a common form of blindness. The company plans to appeal the negative ruling.
Sage Therapeutics and Biogen announced the commercial launch of Zurzuvae, an oral treatment for women with postpartum depression.
Merck and Moderna reported three-year follow-up data on their mRNA-based immunotherapy for advanced melanoma. Phase 3 studies are underway.
The FDA accepted Amgen’s marketing application for tarlatamab, a bispecific antibody to treat advanced small cell lung cancer. The approval decision date is June 12, 2024.

Is it time to worry about Moderna?

Yesterday’s news that Pfizer is expecting to sell far fewer Covid-19 vaccines than Wall Street expected sent shares of Moderna down as much as 6% on fears that the company could be in for a painful revision of its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： 15 die by electrocution after transformer explodes in northern India

WSS

15 die by electrocution after transformer explodes in northern India

STAT Readout Newsletter: Today's biggest biotech updates

Lack of darker skin in textbooks, journals harms patients of color

Why health workers in Gaza are injured or die at high rates

Flagship, Pfizer team up in deal worth up to $7 billion

First Opinion Podcast: Long Covid needs a new approach

focus

Wikipedia

The need-to-know this morning

Is it time to worry about Moderna?

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

The EU Joint Clinical Assessment needs to live up to its promise

Medicare details structure of new drug price negotiation program

Johnson & Johnson sues to stop Medicare negotiation

Duchenne breakthrough therapy leaves behind pioneering families

FDA seeking to stop procedures at two unregulated stem cell clinics

How to save PrEP access — and even expand it

Pharmacists can make shortage drugs, but at what cost?

Jerome Adams on the need for new antivirals for Covid

Pharmacists can make shortage drugs, but at what cost?

hotspot

UnitedHealth’s board chair also owns a personal investment firm

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

Pharmacists can make shortage drugs, but at what cost?

BridgeBio heart drug succeeds in pivotal study

ER docs worry over extreme heat as a 'mass casualty event'

Medicare reduced heart disease by changing how it pays doctors

focus

explore

Wikipedia

knowledge